Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for ENDRA Life Sciences Inc. (NDRA : NSDQ)
 
 • Company Description   
ENDRA Life Sciences Inc. is a developer of enhanced ultrasound technologies. ENDRA Life Sciences Inc. is based in Ann Arbor, United States.

Number of Employees: 22

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.19 Daily Weekly Monthly
20 Day Moving Average: 2,110,655 shares
Shares Outstanding: 44.09 (millions)
Market Capitalization: $8.48 (millions)
Beta: 1.40
52 Week High: $2.44
52 Week Low: $0.18
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -25.47% -18.66%
12 Week -53.45% -50.99%
Year To Date -72.20% -67.60%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
3600 GREEN COURT SUITE 350
-
ANN ARBOR,MI 48105
USA
ph: 734-335-0468
fax: -
ndra@mzgroup.us http://www.endrainc.com
 
 • General Corporate Information   
Officers
Francois Michelon - Chief Executive Officer and Director
Irina Pestrikova - Director
Louis J. Basenese - Director
Anthony DiGiandomenico - Director
Michael Harsh - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED INSTRUMENTS
Sector: Medical
CUSIP: 29273B104
SIC: 3845
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 44.09
Most Recent Split Date: (:1)
Beta: 1.40
Market Capitalization: $8.48 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.05 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.19 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.93
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -16.67%
vs. Previous Quarter: 0.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -98.50
12/31/21 - -79.12
09/30/21 - -78.44
ROA
03/31/22 - -83.88
12/31/21 - -69.83
09/30/21 - -69.25
Current Ratio
03/31/22 - 7.45
12/31/21 - 7.83
09/30/21 - 9.18
Quick Ratio
03/31/22 - 6.03
12/31/21 - 7.00
09/30/21 - 8.22
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 0.21
12/31/21 - 0.26
09/30/21 - 0.31
Inventory Turnover
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.31
12/31/21 - 0.26
09/30/21 - 0.22
 

Powered by Zacks Investment Research ©